ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an update today on its three clinical development programs: RX-3117 (DNA synthesis inhibitor), Supinoxin™ (RX-5902, p68 RNA Helicase inhibitor), and Archexin® (Akt-1 inhibitor). In addition to its three drug candidates in Phase I and Phase II trials, Rexahn has a portfolio of additional compounds, including three in pre-clinical studies.
Help employers find you! Check out all the jobs and post your resume.
